Advisor
Crystal L Mackall MD is the Ernest and Amelia Gallo Family Professor of Pediatrics and Internal Medicine at Stanford University. She serves as Founding Director of the Stanford Center for Cancer Cell Therapy, Associate Director of Stanford Cancer Institute, Leader of the Cancer Immunology and Immunotherapy Program and Director of the Parker Institute for Cancer Immunotherapy at Stanford.
Her work is credited with identifying an essential role for the thymus in human T cell regeneration and discovering IL-7 as the master regulator of T cell homeostasis. She has conducted numerous early phase and first-in-human and first-in-child clinical trials spanning dendritic cell vaccines, cytokines, and adoptive immunotherapy using NK cells and genetically modified T cells.
Her group was among the first to demonstrate impressive activity of CD19-CAR in pediatric leukemia, developed a novel CD22-CAR with impressive activity in leukemia and lymphoma refractory to CD19 targeting, and is leading exciting work focusing on CAR T cell therapy for brain tumors. Her group has identified T cell exhaustion as a major feature limiting the activity of CAR T cells and has developed novel approaches to prevent and reverse human T cell exhaustion.
She is the recipient of numerous awards, including the AACR-St.Baldrick's Award for Outstanding Achievement in Pediatric Cancer Research, the ASCO Pediatric Oncology Award and Lecture, is a member of the American Society of Clinical Investigation, and the American Academy of Physicians. She serves in numerous national leadership positions, including co-PI on the NCI Pediatric Cancer Immunotherapy Network (U54), Leader of the NCI Pediatric Cancer Immunotherapy Trials Network, and co-Leader of the St. Baldrick’s-StandUp2Cancer Pediatric Dream Team. She is Board Certified in Pediatrics, Pediatric Hematology-Oncology and Internal Medicine.